menu

Are You Ready for Biosimilars? What the Oncology Team Should Know

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
Menopause

Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know

Program Information

Part 2: Are You Ready for Biosimilars? What the Oncology Team Should Know
RestartResume

How are biosimilar clinical trials designed to confirm biosimilarity? Find out in the second episode of this two-part video.

  • Sponsored by

  • Overview

    Biosimilars undergo a rigorous evaluation process to ensure high quality and no clinically meaningful difference between biosimilars and the reference product. To learn more about how biosimilar clinical trials are designed to confirm biosimilarity, tune in to the second episode of this two-part series featuring Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC.

                                                                           ©2020 Amgen Inc. All rights reserved. USA-CBU-80729 10/20

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 12/1/20